Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Leonid Koikov is active.

Publication


Featured researches published by Leonid Koikov.


Pigment Cell & Melanoma Research | 2009

α-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes

Zalfa A. Abdel-Malek; Andrew R. Ruwe; Renny Kavanagh-Starner; Ana Luisa Kadekaro; Viki B. Swope; Carrie Haskell-Luevano; Leonid Koikov; James J. Knittel

One skin cancer prevention strategy that we are developing is based on synthesizing and testing melanocortin analogs that reduce and repair DNA damage resulting from exposure to solar ultraviolet (UV) radiation, in addition to stimulating pigmentation. Previously, we reported the effects of tetrapeptide analogs of α‐melanocortin (α‐MSH) that were more potent and stable than the physiological α‐MSH, and mimicked its photoprotective effects against UV‐induced DNA damage in human melanocytes. Here, we report on a panel of tripeptide analogs consisting of a modified α‐MSH core His6‐d‐Phe7‐Arg8, which contained different N‐capping groups, C‐terminal modifications, or arginine mimics. The most potent tripeptides in activating cAMP formation and tyrosinase of human melanocytes were three analogs with C‐terminal modifications. The most effective C‐terminal tripeptide mimicked α‐MSH in reducing hydrogen peroxide generation and enhancing nucleotide excision repair following UV irradiation. The effects of these three analogs required functional MC1R, as they were absent in human melanocytes that expressed non‐functional receptor. These results demonstrate activation of the MC1R by tripeptide melanocortin analogs. Designing small analogs for topical delivery should prove practical and efficacious for skin cancer prevention.


The FASEB Journal | 2006

Melanoma prevention strategy based on using tetrapeptide α-MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity

Zalfa A. Abdel-Malek; Ana Luisa Kadekaro; Renny Kavanagh; Aleksandar Todorovic; Leonid Koikov; Joseph C. McNulty; Pilgrim J. Jackson; Glenn L. Millhauser; Sandy Schwemberger; George F. Babcock; Carrie Haskell-Luevano; James J. Knittel

Melanoma is the deadliest form of skin cancer, with no cure for advanced disease. We propose a strategy for melanoma prevention based on using analogs of α‐melanocyte stimulating hormone (α‐MSH) that function as melanocortin 1 receptor (MC1R) agonists. Treatment of human melanocytes with α‐MSH results in stimulation of eumelanin synthesis, reduction of apoptosis that is attributable to reduced hydrogen peroxide generation and enhanced repair of DNA photoproducts. These effects should contribute to genomic stability of human melanocytes, thus preventing their malignant transformation to melanoma. Based on these findings, we synthesized and tested the effects of 3 tetrapeptide α‐MSH analogs, Ac‐His‐D‐Phe‐Arg‐Trp‐NH2, n‐Pentadecanoyl‐ and 4‐Phenylbutyryl‐His‐D‐Phe‐Arg‐Trp‐NH2, on cultured human melanocytes. The latter two analogs were more potent than the former, or α‐MSH, in stimulating the activity of tyrosinase, thus melanogenesis, reducing apoptosis and release of hydrogen peroxide and enhancing repair of DNA photoproducts in melanocytes exposed to UV radiation (UVR). The above analogs are MC1R agonists, as their effects were abrogated by an analog of agouti signaling protein, the physiological MC1R antagonist, and were absent in melanocytes expressing loss‐of‐function MC1R. Analogs, such as 4‐Phenylbutyryl‐His‐D‐Phe‐Arg‐Trp‐NH2 with prolonged and reversible effects, can potentially be developed into topical agents to prevent skin photocarcinogenesis, particularly melanoma.—Abdel‐Malek, Z. A., Kadekaro, A. L., Kavanagh, R. J., Todorovic, A., Koikov, L. N., McNulty, J. C., Jackson, P. J., Millhauser, G. L., Schwemberger, S., Babcock, G., Haskell‐Luevano, C., Knittel, J. J. Melanoma prevention strategy based on using tetrapeptide α‐MSH analogs that protect human melanocytes from UV‐induced DNA damage and cytotoxicity. FASEB J. 20, E888–E896 (2006)


Bioorganic & Medicinal Chemistry Letters | 2003

Sub-Nanomolar hMC1R Agonists by End-Capping of the Melanocortin Tetrapeptide His-d-Phe-Arg-Trp-NH2

Leonid Koikov; Frank H. Ebetino; Mark Gregory Solinsky; Doreen Crossdoersen; James J. Knittel

Twenty three derivatives of the core fragment His(6)-D-Phe(7)-Arg(8)-Trp(9)-NH(2) end-capped with carboxylic and sulfonic acids were synthesized and evaluated at human melanocortin receptors (hMC1, hMC3, and hMC4Rs). The SAR within this series allowed us to map the hMCRs near the His(6) binding site and design a superpotent MC1R agonist, LK-184, Ph(CH(2))(3)CO-His-D-Phe-Arg-Trp-NH(2) (19) with EC(50) 0.01 nM (5 nM at MC3 and MC4Rs).


Archives of Biochemistry and Biophysics | 2014

Melanocortins and the melanocortin 1 receptor, moving translationally towards melanoma prevention.

Zalfa A. Abdel-Malek; Viki B. Swope; Renny J. Starner; Leonid Koikov; Pamela B. Cassidy; Sancy A. Leachman

Beginning in the last decade of the twentieth century, the fields of pigment cell research and melanoma have witnessed major breakthroughs in the understanding of the role of melanocortins in human pigmentation and the DNA damage response of human melanocytes to solar ultraviolet radiation (UV). This began with the cloning of the melanocortin 1 receptor (MC1R) gene from human melanocytes and the demonstration that the encoded receptor is functional. Subsequently, population studies found that the MC1R gene is highly polymorphic, and that some of its variants are associated with red hair phenotype, fair skin and poor tanning ability. Using human melanocytes cultured from donors with different MC1R genotypes revealed that the alleles associated with red hair color encode for a non-functional receptor. Epidemiological studies linked the MC1R red hair color variants to increased melanoma risk. Investigating the impact of different MC1R variants on the response of human melanocytes to UV led to the important discovery that the MC1R signaling activates antioxidant, DNA repair and survival pathways, in addition to stimulation of eumelanin synthesis. These effects of MC1R were absent in melanocytes expressing 2 MC1R red hair color variants that result in loss of function of the receptor. The importance of the MC1R in reducing UV-induced genotoxicity in melanocytes led us to design small peptide analogs of the physiological MC1R agonist α-melanocortin (α-melanocyte stimulating hormone; α-MSH) for the goal of utilizing them for melanoma chemoprevention.


Bioorganic & Medicinal Chemistry Letters | 2009

Exploring the PI3Kα and γ binding sites with 2,6-disubstituted isonicotinic derivatives

Philip T. Cherian; Leonid Koikov; Matthew Wortman; James J. Knittel

A homology model of the p110alpha catalytic subunit of PI3Kalpha was generated from the p110gamma crystal structure. Using this model, an isonicotinic scaffold was designed for chemically exploring the PI3Kalpha and gamma binding sites. A focused library of derivatives was synthesized and tested. The morpholine acids 5a and 5b proved to be the most potent analogs.


Bioorganic & Medicinal Chemistry Letters | 2009

Semi-rigid tripeptide agonists of melanocortin receptors

Andrew R. Ruwe; Leonid Koikov; Zalfa A. Abdel-Malek; Carrie Haskell-Luevano; Marvin Dirain; Federico P. Portillo; Zhimin Xiang; Matthew Wortman; James J. Knittel

A series of 30 RCO-HfR-NH(2) derivatives show preference for the mouse MC1R vs MC3-5Rs. trans-4-HOC(6)H(4)CH=CHCO-HfR-NH(2) (13) [EC(50) (nM): MC1R 83, MC3R 20500, MC4R 18130 and MC5R 935; ratio 1:246:217:11] is 11 times more potent than the lead compound LK-394 Ph(CH(2))(3)CO-HfR-NH(2) (2) and only 11 times less potent than the native tridecapeptide alpha-MSH at mMC1R. Differences in conformations of 2 and 13 are discussed.


Bioorganic & Medicinal Chemistry Letters | 2004

Analogs of sub-nanomolar hMC1R agonist LK-184 [Ph(CH2)3CO-His-d-Phe-Arg-Trp-NH2]. An additional binding site within the human melanocortin receptor 1?

Leonid Koikov; Frank H. Ebetino; Mark Gregory Solinsky; Doreen Crossdoersen; James J. Knittel


Bioorganic & Medicinal Chemistry Letters | 2004

End-capping of the modified melanocortin tetrapeptide (p-Cl)Phe-D-Phe-Arg-Trp-NH2 as a route to hMC4R agonists.

Leonid Koikov; Frank H. Ebetino; J.C. Hayes; Doreen Crossdoersen; James J. Knittel


Archive | 2013

Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor

Zalfa A. Abdel-Malek; Leonid Koikov; James J. Knittel


Archive | 2017

Pharmaceutical compositions comprising selective peptide-based agonists of melanocortin 1 receptor

Zalfa A. Abdel-Malek; Leonid Koikov; James J. Knittel

Collaboration


Dive into the Leonid Koikov's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew R. Ruwe

University of Cincinnati

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Renny Kavanagh

University of Cincinnati

View shared research outputs
Researchain Logo
Decentralizing Knowledge